Pharmacology of L-type calcium channels: Novel drugs for old targets?

Current Molecular Pharmacology

Volumn 8, Issue 2, 2015, Pages 110-122

  Striessnig, Jörg ^a   Ortner, Nadine J ^a   Pinggera, Alexandra ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Calcium homeostasis; Drug discovery L type channels; Neuropsychiatric disorders; Pharmacology; Voltage gated calcium channels

Indexed keywords

CALCIUM CHANNEL L TYPE; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; ISOPROTEIN; PROTEIN SUBUNIT;

ADVERSE OUTCOME; AUTISM; BRAIN; CARDIOVASCULAR SYSTEM; CHEMICAL STRUCTURE; CLINICAL TRIAL (TOPIC); DOPAMINERGIC NERVE CELL; DRUG SELECTIVITY; DRUG TARGETING; EMOTION; ENDOCRINE CELL; FEBRILE CONVULSION; HEART FAILURE; HIPPOCAMPUS; HUMAN; MEMORY; MENTAL DISEASE; MOLECULAR PATHOLOGY; NERVE CELL DIFFERENTIATION; NEUROPHYSIOLOGY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; REVIEW; VESTIBULAR SYSTEM; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CHANNEL GATING; CLASSIFICATION; DRUG EFFECTS; GENETICS; METABOLISM; MUTATION; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN SUBUNIT;

ANTIHYPERTENSIVE AGENTS; BRAIN; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; HUMANS; ION CHANNEL GATING; MODELS, BIOLOGICAL; MUTATION; PROTEIN ISOFORMS; PROTEIN SUBUNITS;

EID: 84940998956     PISSN: 18744672     EISSN: 18744702     Source Type: Journal    
DOI: 10.2174/1874467208666150507105845     Document Type: Review

References (117)

1. Catterall, W. A.; Perez-Reyes, E.; Snutch, T. P.; Striessnig, J. International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol. Rev., 2005, 57(4), 411-425.
2. Striessnig, J.; Pinggera, A.; Kaur, G.; Bock, G.; Tuluc, P. L-type calcium channels in heart and brain. Wiley Interdiscip Rev Membr Transp Signal, 2014, doi: 10. 1002/wmts. 102.
3. Simms, B. A.; Zamponi, G. W. Neuronal voltage-gated calcium channels: structure, function, and dysfunction. Neuron, 2014, 82(1), 24-45.
4. Christel, C.; Lee, A. Ca2+-dependent modulation of voltage-gated Ca2+ channels. Biochim. Biophys. Acta, 2012, 1820(8), 1243-1252.
5. Dolphin, A. C. The alpha2delta subunits of voltage-gated calcium channels. Biochim. Biophys. Acta, 2013, 1828(7), 1541-1549.
6. Dragicevic, E.; Poetschke, C.; Duda, J.; Schlaudraff, F.; Lammel, S.; Schiemann, J.; Fauler, M.; Hetzel, A.; Watanabe, M.; Lujan, R.; Malenka, R. C.; Striessnig, J.; Liss, B. Cav1. 3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons. Brain, 2014, 137, 2287-2302.
7. Tuluc, P.; Molenda, N.; Schlick, B.; Obermair, G. J.; Flucher, B. E.; Jurkat-Rott, K. A Cav1. 1 Ca2+ channel splice variant with high conductance and voltage-sensitivity alters EC coupling in developing skeletal muscle. Biophys J, 2009, 96(1), 35-44.
8. Striessnig, J.; Koschak, A. Exploring the function and pharmacotherapeutic potential of voltage-gated Ca2+ channels with gene knockout models. Channels(Austin), 2008, 2(4), 233-251.
9. Lu, L.; Sirish, P.; Zhang, Z.; Woltz, R. L.; Li, N.; Timofeyev, V.; Knowlton, A. A.; Zhang, X.-D.; Yamoah, E. N.; Chiamvimonvat, N. Regulation of Gene Transcription by Voltage-Gated L-Type Calcium Channel, Cav1. 3. J. Biol. Chem., 2015, 290, 4663-4676.
10. Koschak, A.; Reimer, D.; Huber, I.; Grabner, M.; Glossmann, H.; Engel, J.; Striessnig, J. EE1D (Cav1. 3) subunits can form L-type calcium channels activating at negative voltages. J. Biol. Chem., 2001, 276(25), 22100-22106.
11. Bock, G.; Gebhart, M.; Scharinger, A.; Jangsangthong, W.; Busquet, P.; Poggiani, C.; Sartori, S.; Mangoni, M. E.; Sinnegger-Brauns, M. J.; Herzig, S.; Striessnig, J.; Koschak, A. Functional properties of a newly identified C-terminal splice variant of Cav1. 3 L-type Ca2+ channels. J. Biol. Chem., 2011, 286(49), 42736-42748.
12. Mangoni, M. E.; Nargeot, J. Genesis and regulation of the heart automaticity. Physiol. Rev., 2008, 88(3), 919-982.
13. Olson, P. A.; Tkatch, T.; Hernandez-Lopez, S.; Ulrich, S.; Ilijic, E.; Mugnaini, E.; Zhang, H.; Bezprozvanny, I.; Surmeier, D. J. Gprotein-coupled receptor modulation of striatal Cav1. 3 L-type calcium channels is dependent on a Shank-binding domain. J. Neurosci., 2005, 25(5), 1050-1062.
14. Vandael, D. H.; Mahapatra, S.; Calorio, C.; Marcantoni, A.; Carbone, E. Cav1. 3 and Cav1. 2 channels of adrenal chromaffin cells: Emerging views on cAMP/cGMP-mediated phosphorylation and role in pacemaking. Biochim. Biophys. Acta, 2013, 1828(7), 1608-1618.
15. Tikhonov, D. B.; Zhorov, B. S. Structural model for dihydropyridine binding to L-type calcium channels. J. Biol. Chem., 2009, 284(28), 19006-19017.
16. Striessnig, J.; Grabner, M.; Mitterdorfer, J.; Hering, S.; Sinnegger, M. J.; Glossmann, H. Structural basis of drug binding to L Ca2+ channels. Trends Pharmacol. Sci., 1998, 19(3), 108-115.
17. Striessnig, J.; Hoda, J. C.; Wappl, E.; Koschak, A. The molecular basis of calcium antagonist drug action-recent developments. In: Voltage-gated calciumm channels, Zamponi, G. W., Ed.; Landes Biosciences; 2005.
18. Bean, B. P.; Sturek, M.; Puga, A.; Hermsmeyer, K. Calcium channels in muscle cells isolated from rat mesenteric arteries: modulation by dihydropyridine drugs. Circ. Res., 1986, 59(2), 229-235.
19. Berjukow, S.; Hering, S. Voltage-dependent acceleration of Cav1. 2 channel current decay by (+)-and (-)-isradipine. Br. J. Pharmacol., 2001, 133(7), 959-966.
20. Hamilton, S. L.; Yatani, A.; Brush, K.; Schwartz, A.; Brown, A. M. A comparison between the binding and electrophysiological effects of dihydropyridines on cardiac membranes. Mol. Pharmacol., 1987, 31(3), 221-231.
21. Beyl, S.; Timin, E. N.; Hohaus, A.; Stary, A.; Kudrnac, M.; Guy, R. H.; Hering, S. Probing the architecture of an L-type calcium channel with a charged phenylalkylamine: evidence for a widely open pore and drug trapping. J. Biol. Chem., 2007, 282(6), 3864-3870.
22. Hering, S.; Aczel, S.; Kraus, R. L.; Berjukow, S.; Striessnig, J.; Timin, E. N. Molecular mechanism of use-dependent calcium channel block by phenylalkylamines: role of inactivation. Proc. Natl. Acad. Sci. USA, 1997, 94(24), 13323-13328.
23. Shabbir, W.; Beyl, S.; Timin, E. N.; Schellmann, D.; Erker, T.; Hohaus, A.; Hockerman, G. H.; Hering, S. Interaction of diltiazem with an intracellularly accessible binding site on Cav1. 2. Br. J. Pharmacol., 2011, 162(5), 1074-1082.
24. Fleischmann, B. K.; Murray, R. K.; Kotlikoff, M. I. Voltage window for sustained elevation of cytosolic calcium in smooth muscle cells. Proc. Natl. Acad. Sci. USA, 1994, 91(25), 11914-11918.
25. Marcantoni, A.; Vandael, D. H.; Mahapatra, S.; Carabelli, V.; Sinnegger-Brauns, M. J.; Striessnig, J.; Carbone, E. Loss of Cav1. 3 channels reveals the critical role of L-type and BK channel coupling in pacemaking mouse adrenal chromaffin cells. J. Neurosci., 2010, 30(2), 491-504.
26. Mangoni, M. E.; Couette, B.; Bourinet, E.; Platzer, J.; Reimer, D.; Striessnig, J.; Nargeot, J. Functional role of L-type Cav1. 3 calcium channels in cardiac pacemaker activity. Proc Natl Acad Sci U S A, 2003, 100(9), 5543-5548.
27. Lieb, A.; Ortner, N.; Striessnig, J. C-terminal modulatory domain controls coupling of voltage-sensing to pore opening in Cav1. 3 Ltype calcium channels. Biophys. J., 2014, 106(7), 1467-1475.
28. Xu, W.; Lipscombe, D. Neuronal Cav1. 3111 L-type channels activate at relatively hyperpolarized membrane potentials and are incompletely inhibited by dihydropyridines. J. Neurosci., 2001, 21(16), 5944-5951.
29. Welling, A.; Kwan, Y. W.; Bosse, E.; Flockerzi, V.; Hofmann, F.; Kass, R. S. Subunit-dependent modulation of recombinant L-type calcium channels. Molecular basis for dihydropyridine tissue selectivity. Circ. Res., 1993, 73(5), 974-980.
30. Catterall, W. A. Voltage-gated calcium channels. Cold Spring Harb Perspect Biol, 2011, 3(8), a003947.
31. Baig, S. M.; Koschak, A.; Lieb, A.; Gebhart, M.; Dafinger, C.; Nurnberg, G.; Ali, A.; Ahmad, I.; Sinnegger-Brauns, M. J.; Brandt, N.; Engel, J.; Mangoni, M. E.; Farooq, M.; Khan, H. U.; Nurnberg, P.; Striessnig, J.; Bolz, H. J. Loss of Cav1. 3 (CACNA1D) function in a human channelopathy with bradycardia and congenital deafness. Nat. Neurosci., 2011, 14(1), 77-84.
32. Oliver, D.; Knipper, M.; Derst, C.; Fakler, B.; Liberman, M. C.; Gao, J.; He, D. Z.; Wu, X.; Jia, S.; Zuo, J. Resting potential and submembrane calcium concentration of inner hair cells in the isolated mouse cochlea are set by KCNQ-type potassium channels. J. Neurosci., 2003, 23(6), 2141-2149.
33. Michna, M.; Knirsch, M.; Hoda, J. C.; Muenkner, S.; Langer, P.; Platzer, J.; Striessnig, J.; Engel, J. Cav1. 3 (111D) calcium currents in neonatal outer hair cells of mice. J. Physiol., 2003, 553(Pt. 3), 747-758.
34. Platzer, J.; Engel, J.; Schrott-Fischer, A.; Stephan, K.; Bova, S.; Chen, H.; Zheng, H.; Striessnig, J. Congenital deafness and sinoatrial node dysfunction in mice lacking class D L-type calcium channels. Cell, 2000, 102(1), 89-97.
35. Sinnegger-Brauns, M. J.; Huber, I. G.; Koschak, A.; Wild, C.; Obermair, G. J.; Einzinger, U.; Hoda, J. C.; Sartori, S. B.; Striessnig, J. Expression and 1, 4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol. Pharmacol., 2009, 75(2), 407-414.
36. Pichler, M.; Cassidy, T. N.; Reimer, D.; Haase, H.; Kraus, R.; Ostler, D.; Striessnig, J. Beta subunit heterogeneity in neuronal Ltype calcium channels. J. Biol. Chem., 1997, 272, 13877-13882.
37. Tan, B. Z.; Jiang, F.; Tan, M. Y.; Yu, D.; Huang, H.; Shen, Y.; Soong, T. W. Functional characterization of alternative splicing in the C terminus of L-type CaV1. 3 channels. J. Biol. Chem., 2011, 286(49), 42725-42735.
38. Huang, H.; Tan, B. Z.; Shen, Y.; Tao, J.; Jiang, F.; Sung, Y. Y.; Ng, C. K.; Raida, M.; Kohr, G.; Higuchi, M.; Fatemi-Shariatpanahi, H.; Harden, B.; Yue, D. T.; Soong, T. W. RNA editing of the IQ domain in Cav1. 3 channels modulates their Ca2+-dependent inactivation. Neuron, 2012, 73(2), 304-316.
39. Di Biase, V.; Obermair, G. J.; Szabo, Z.; Altier, C.; Sanguesa, J.; Bourinet, E.; Flucher, B. E. Stable membrane expression of postsynaptic Cav1. 2 calcium channel clusters is independent of interactions with AKAP79/150 and PDZ proteins. J. Neurosci., 2008, 28(51), 13845-13855.
40. Jenkins, M. A.; Christel, C. J.; Jiao, Y.; Abiria, S.; Kim, K. Y.; Usachev, Y. M.; Obermair, G. J.; Colbran, R. J.; Lee, A. Ca2+-dependent facilitation of Cav1. 3 Ca2+ channels by densin and Ca2+/calmodulin-dependent protein kinase II. J. Neurosci., 2010, 30(15), 5125-5135.
41. Moosmang, S.; Haider, N.; Klugbauer, N.; Adelsberger, H.; Langwieser, N.; Muller, J.; Stiess, M.; Marais, E.; Schulla, V.; Lacinova, L.; Goebbels, S.; Nave, K. A.; Storm, D. R.; Hofmann, F.; Kleppisch, T. Role of hippocampal Cav1. 2 calcium channels in NMDA receptor-independent synaptic plasticity and spatial memory. J. Neurosci., 2005, 25(43), 9883-9892.
42. White, J. A.; McKinney, B. C.; John, M. C.; Powers, P. A.; Kamp, T. J.; Murphy, G. G. Conditional forebrain deletion of the L-type calcium channel Cav1. 2 disrupts remote spatial memories in mice. Learn. Mem., 2008, 15(1), 1-5.
43. McKinney, B. C.; Murphy, G. G. The L-Type voltage-gated calcium channel Cav1. 3 mediates consolidation, but not extinction, of contextually conditioned fear in mice. Learn. Mem., 2006, 13(5), 584-589.
44. Busquet, P.; Hetzenauer, A.; Sinnegger-Brauns, M. J.; Striessnig, J.; Singewald, N. Role of L-type calcium channel isoforms in the extinction of conditioned fear. Learn. Mem., 2008, 15(5), 378-386.
45. McKinney, B. C.; Sze, W.; Lee, B.; Murphy, G. G. Impaired longterm potentiation and enhanced neuronal excitability in the amygdala of Cav1. 3 knockout mice. Neurobiol. Learn. Mem., 2009, 92(4), 519-528.
46. Langwieser, N.; Christel, C. J.; Kleppisch, T.; Hofmann, F.; Wotjak, C. T.; Moosmang, S. Homeostatic switch in hebbian plasticity and fear learning after sustained loss of Cav1. 2 calcium channels. J. Neurosci., 2010, 30(25), 8367-8375.
47. Jeon, D.; Kim, S.; Chetana, M.; Jo, D.; Ruley, H. E.; Lin, S. Y.; Rabah, D.; Kinet, J. P.; Shin, H. S. Observational fear learning involves affective pain system and Cav1. 2 Ca2+ channels in ACC. Nat. Neurosci., 2010, 13(4), 482-488.
48. Lee, A. S.; Ra, S.; Rajadhyaksha, A. M.; Britt, J. K.; De Jesus-Cortes, H.; Gonzales, K. L.; Lee, A.; Moosmang, S.; Hofmann, F.; Pieper, A. A.; Rajadhyaksha, A. M. Forebrain elimination of cacna1c mediates anxiety-like behavior in mice. Mol. Psychiatry, 2012, 17(11), 1054-1055.
49. Busquet, P.; Nguyen, N. K.; Schmid, E.; Tanimoto, N.; Seeliger, M. W.; Ben-Yosef, T.; Mizuno, F.; Akopian, A.; Striessnig, J.; Singewald, N. Cav1. 3 L-type calcium channels modulate depression-like behaviour in mice independent of deaf phenotype. Int. J. Neuropsychopharmacol., 2010, 13(4), 499-513.
50. Sinnegger-Brauns, M. J.; Hetzenauer, A.; Huber, I. G.; Renstrom, E.; Wietzorrek, G.; Berjukov, S.; Cavalli, M.; Walter, D.; Koschak, A.; Waldschutz, R.; Hering, S.; Bova, S.; Rorsman, P.; Pongs, O.; Singewald, N.; Striessnig, J. Isoform-specific regulation of mood behavior and pancreatic beta cell and cardiovascular function by Ltype Calcium channels. J. Clin. Invest., 2004, 113(10), 1430-1439.
51. Hetzenauer, A.; Sinnegger-Brauns, M. J.; Striessnig, J.; Singewald, N. Brain activation pattern induced by stimulation of L-type Ca2+-channels: contribution of Cav1. 3 and Cav1. 2 isoforms. Neuroscience, 2006, 139(3), 1005-1015.
52. Giordano, T. P.; Tropea, T. F.; Satpute, S. S.; Sinnegger-Brauns, M. J.; Striessnig, J.; Kosofsky, B. E.; Rajadhyaksha, A. M. Molecular switch from L-type Cav1. 3 to Cav1. 2 Ca2+ channel signaling underlies long-term psychostimulant-induced behavioral and molecular plasticity. J. Neurosci., 2010, 30(50), 17051-17062.
53. Fieblinger, T.; Graves, S. M.; Sebel, L. E.; Alcacer, C.; Plotkin, J. L.; Gertler, T. S.; Chan, C. S.; Heiman, M.; Greengard, P.; Cenci, M. A.; Surmeier, D. J. Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia. Nat. Commun., 2014, 5, 5316.
54. Liss, B.; Roeper, J. Individual dopamine midbrain neurons: functional diversity and flexibility in health and disease. Brain Res. Rev., 2008, 58(2), 314-321.
55. Chan, C. S.; Guzman, J. N.; Ilijic, E.; Mercer, J. N.; Rick, C.; Tkatch, T.; Meredith, G. E.; Surmeier, D. J. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature, 2007, 447(7148), 1081-1086.
56. Ilijic, E.; Guzman, J. N.; Surmeier, D. J. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease. Neurobiol. Dis., 2011, 43(2), 364-371.
57. Kupsch, A.; Gerlach, M.; Pupeter, S. C.; Sautter, J.; Dirr, A.; Arnold, G.; Opitz, W.; Przuntek, H.; Riederer, P.; Oertel, W. H. Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice. Neuroreport., 1995, 6(4), 621-625.
58. Kupsch, A.; Sautter, J.; Schwarz, J.; Riederer, P.; Gerlach, M.; Oertel, W. H. 1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridineinduced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Brain Res., 1996, 741(1-2), 185-196.
59. Surmeier, D. J.; Guzman, J. N.; Sanchez-Padilla, J.; Goldberg, J. A. The origins of oxidant stress in Parkinson's disease and therapeutic strategies. Antioxid. Redox. Signal., 2011, 14(7), 1289-1301.
60. Guzman, J. N.; Sanchez-Padilla, J.; Chan, C. S.; Surmeier, D. J. Robust pacemaking in substantia nigra dopaminergic neurons. J. Neurosci., 2009, 29(35), 11011-11019.
61. Dragicevic, E.; Schiemann, J.; Liss, B. Dopamine midbrain neurons in health and Parkinson's disease: Emerging roles of voltage-gated calcium channels and ATP-sensitive potassium channels. Neuroscience, 2015, 284C, 798-814.
62. Putzier, I.; Kullmann, P. H.; Horn, J. P.; Levitan, E. S. Cav1. 3 channel voltage dependence, not Ca2+ selectivity, drives pacemaker activity and amplifies bursts in nigral dopamine neurons. J. Neurosci., 2009, 29(49), 15414-15419.
63. Mosharov, E. V.; Larsen, K. E.; Kanter, E.; Phillips, K. A.; Wilson, K.; Schmitz, Y.; Krantz, D. E.; Kobayashi, K.; Edwards, R. H.; Sulzer, D. Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron, 2009, 62(2), 218-229.
64. Dragicevic, E.; Poetschke, C.; Duda, J.; Schlaudraff, F.; Lammel, S.; Schiemann, J.; Fauler, M.; Hetzel, A.; Watanabe, M.; Lujan, R.; Malenka, R. C.; Striessnig, J.; Liss, B. Cav1. 3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons. Brain, 2014, 137(Pt. 8), 2287-2302.
65. Hirtz, J. J.; Braun, N.; Griesemer, D.; Hannes, C.; Janz, K.; Lohrke, S.; Muller, B.; Friauf, E. Synaptic refinement of an inhibitory topographic map in the auditory brainstem requires functional Cav1. 3 calcium channels. J. Neurosci., 2012, 32(42), 14602-14616.
66. Hirtz, J. J.; Boesen, M.; Braun, N.; Deitmer, J. W.; Kramer, F.; Lohr, C.; Muller, B.; Nothwang, H. G.; Striessnig, J.; Lohrke, S.; Friauf, E. Cav1. 3 calcium channels are required for normal development of the auditory brainstem. J. Neurosci., 2011, 31(22), 8280-8294.
67. Satheesh, S. V.; Kunert, K.; Ruttiger, L.; Zuccotti, A.; Schonig, K.; Friauf, E.; Knipper, M.; Bartsch, D.; Nothwang, H. G. Retrocochlear function of the peripheral deafness gene Cacna1d. Hum. Mol. Genet., 2012, 21(17), 3896-3909.
68. Splawski, I.; Timothy, K. W.; Sharpe, L. M.; Decher, N.; Kumar, P.; Bloise, R.; Napolitano, C.; Schwartz, P. J.; Joseph, R. M.; Condouris, K.; Tager-Flusberg, H.; Priori, S. G.; Sanguinetti, M. C.; Keating, M. T. Cav1. 2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell, 2004, 119(1), 19-31.
69. Bader, P. L.; Faizi, M.; Kim, L. H.; Owen, S. F.; Tadross, M. R.; Alfa, R. W.; Bett, G. C.; Tsien, R. W.; Rasmusson, R. L.; Shamloo, M. Mouse model of Timothy syndrome recapitulates triad of autistic traits. Proc. Natl. Acad. Sci. USA, 2011, 108(37), 15432-15437.
70. Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet, 2013, 381(9875), 1371-1379.
71. Bhat, S.; Dao, D. T.; Terrillion, C. E.; Arad, M.; Smith, R. J.; Soldatov, N. M.; Gould, T. D. CACNA1C (Cav1. 2) in the pathophysiology of psychiatric disease. Prog. Neurobiol., 2012, 99(1), 1-14.
72. O'Roak, B. J.; Vives, L.; Girirajan, S.; Karakoc, E.; Krumm, N.; Coe, B. P.; Levy, R.; Ko, A.; Lee, C.; Smith, J. D.; Turner, E. H.; Stanaway, I. B.; Vernot, B.; Malig, M.; Baker, C.; Reilly, B.; Akey, J. M.; Borenstein, E.; Rieder, M. J.; Nickerson, D. A.; Bernier, R.; Shendure, J.; Eichler, E. E. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature, 2012, 485(7397), 246-250.
73. Iossifov, I.; Ronemus, M.; Levy, D.; Wang, Z.; Hakker, I.; Rosenbaum, J.; Yamrom, B.; Lee, Y. H.; Narzisi, G.; Leotta, A.; Kendall, J.; Grabowska, E.; Ma, B.; Marks, S.; Rodgers, L.; Stepansky, A.; Troge, J.; Andrews, P.; Bekritsky, M.; Pradhan, K.; Ghiban, E.; Kramer, M.; Parla, J.; Demeter, R.; Fulton, L. L.; Fulton, R. S.; Magrini, V. J.; Ye, K.; Darnell, J. C.; Darnell, R. B.; Mardis, E. R.; Wilson, R. K.; Schatz, M. C.; McCombie, W. R.; Wigler, M. De novo gene disruptions in children on the autistic spectrum. Neuron, 2012, 74(2), 285-299.
74. Scholl, U. I.; Goh, G.; Stolting, G.; de Oliveira, R. C.; Choi, M.; Overton, J. D.; Fonseca, A. L.; Korah, R.; Starker, L. F.; Kunstman, J. W.; Prasad, M. L.; Hartung, E. A.; Mauras, N.; Benson, M. R.; Brady, T.; Shapiro, J. R.; Loring, E.; Nelson-Williams, C.; Libutti, S. K.; Mane, S.; Hellman, P.; Westin, G.; Akerstrom, G.; Bjorklund, P.; Carling, T.; Fahlke, C.; Hidalgo, P.; Lifton, R. P. Somatic and germline CACNA1D calcium channel mutations in aldosteroneproducing adenomas and primary aldosteronism. Nat. Genet., 2013, 45(9), 1050-1054.
75. Hofmann, F.; Flockerzi, V.; Kahl, S.; Wegener, J. W. L-Type CaV1. 2 Calcium Channels: From In vitro Findings to In vivo Function. Physiol. Rev., 2014, 94(1), 303-326.
76. Braun, M.; Ramracheya, R.; Bengtsson, M.; Zhang, Q.; Karanauskaite, J.; Partridge, C.; Johnson, P. R.; Rorsman, P. Voltage-gated ion channels in human pancreatic beta-cells: electrophysiological characterization and role in insulin secretion. Diabetes, 2008, 57(6), 1618-1628.
77. Levine, M.; Boyer, E. W.; Pozner, C. N.; Geib, A. J.; Thomsen, T.; Mick, N.; Thomas, S. H. Assessment of hyperglycemia after calcium channel blocker overdoses involving diltiazem or verapamil. Crit. Care Med., 2007, 35(9), 2071-2075.
78. Vandael, D. H.; Zuccotti, A.; Striessnig, J.; Carbone, E. Cav1. 3-driven SK channel activation regulates pacemaking and spike frequency adaptation in mouse chromaffin cells. J. Neurosci., 2012, 32(46), 16345-16359.
79. Azizan, E. A.; Poulsen, H.; Tuluc, P.; Zhou, J.; Clausen, M. V.; Lieb, A.; Maniero, C.; Garg, S.; Bochukova, E. G.; Zhao, W.; Shaikh, L. H.; Brighton, C. A.; Teo, A. E.; Davenport, A. P.; Dekkers, T.; Tops, B.; Kusters, B.; Ceral, J.; Yeo, G. S.; Neogi, S. G.; McFarlane, I.; Rosenfeld, N.; Marass, F.; Hadfield, J.; Margas, W.; Chaggar, K.; Solar, M.; Deinum, J.; Dolphin, A. C.; Farooqi, I. S.; Striessnig, J.; Nissen, P.; Brown, M. J. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat. Genet., 2013, 45(9), 1055-1060.
80. Hu, C.; Rusin, C. G.; Tan, Z.; Guagliardo, N. A.; Barrett, P. Q. Zona glomerulosa cells of the mouse adrenal cortex are intrinsic electrical oscillators. J. Clin. Invest., 2012, 122(6), 2046-2053.
81. Moosmang, S.; Schulla, V.; Welling, A.; Feil, R.; Feil, S.; Wegener, J. W.; Hofmann, F.; Klugbauer, N. Dominant role of smooth muscle L-type calcium channel Cav1. 2 for blood pressure regulation. EMBO J., 2003, 22(22), 6027-6034.
82. Zhang, J.; Berra-Romani, R.; Sinnegger-Brauns, M. J.; Striessnig, J.; Blaustein, M. P.; Matteson, D. R. Role of Cav1. 2 L-type calcium channels in vascular tone: effects of nifedipine and Mg2+. Am. J. Physiol. Heart Circ. Physiol., 2007, 292(1), H415-425.
83. Zhang, Z.; He, Y.; Tuteja, D.; Xu, D.; Timofeyev, V.; Zhang, Q.; Glatter, K. A.; Xu, Y.; Shin, H. S.; Low, R.; Chiamvimonvat, N. Functional roles of Cav1. 3(111D) calcium channels in atria: insights gained from gene-targeted null mutant mice. Circulation, 2005, 112(13), 1936-1944.
84. Liao, P.; Yu, D.; Li, G.; Yong, T. F.; Soon, J. L.; Chua, Y. L.; Soong, T. W. A smooth muscle Cav1. 2 calcium channel splice variant underlies hyperpolarized window current and enhanced statedependent inhibition by nifedipine. J. Biol. Chem., 2007, 282(48), 35133-35142.
85. Huang, H.; Yu, D.; Soong, T. W. C-Terminal alternative splicing of CaV1. 3 channels distinctively modulates their dihydropyridine sensitivity. Mol. Pharmacol., 2013, 84(4), 643-653.
86. Uchida, S.; Yamada, S.; Nagai, K.; Deguchi, Y.; Kimura, R. Brain pharmacokinetics and in vivo receptor binding of 1, 4-dihydropyridine calcium channel antagonists. Life Sci., 1997, 61(21), 2083-2090.
87. Allen, G. S.; Ahn, H. S.; Preziosi, T. J.; Battye, R.; Boone, S. C.; Boone, S. C.; Chou, S. N.; Kelly, D. L.; Weir, B. K.; Crabbe, R. A.; Lavik, P. J.; Rosenbloom, S. B.; Dorsey, F. C.; Ingram, C. R.; Mellits, D. E.; Bertsch, L. A.; Boisvert, D. P.; Hundley, M. B.; Johnson, R. K.; Strom, J. A.; Transou, C. R. Cerebral arterial spasm-a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N. Engl. J. Med., 1983, 308(11), 619-624.
88. Helton, T. D.; Xu, W.; Lipscombe, D. Neuronal L-type calcium channels open quickly and are inhibited slowly. J. Neurosci., 2005, 25(44), 10247-10251.
89. Wankerl, K.; Weise, D.; Gentner, R.; Rumpf, J. J.; Classen, J. Ltype voltage-gated calcium channels: a single molecular switch for long-term potentiation/long-term depression-like plasticity and activity-dependent metaplasticity in humans. J. Neurosci., 2010, 30(18), 6197-6204.
90. Waltereit, R.; Mannhardt, S.; Nescholta, S.; Maser-Gluth, C.; Bartsch, D. Selective and protracted effect of nifedipine on fear memory extinction correlates with induced stress response. Learn. Mem., 2008, 15(5), 348-356.
91. McKinney, B. C.; Sze, W.; White, J. A.; Murphy, G. G. L-type voltage-gated calcium channels in conditioned fear: a genetic and pharmacological analysis. Learn. Mem., 2008, 15(5), 326-334.
92. Group, P. S. Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD). Mov. Disord., 2013, 28(13), 1823-1831.
93. Ritz, B.; Rhodes, S. L.; Qian, L.; Schernhammer, E.; Olsen, J. H.; Friis, S. L-type calcium channel blockers and Parkinson disease in Denmark. Ann Neurol, 2010, 67(5), 600-606.
94. Becker, C.; Jick, S. S.; Meier, C. R. Use of antihypertensives and the risk of Parkinson disease. Neurology, 2008, 70(16 Pt. 2), 1438-1444.
95. Pasternak, B.; Svanstrom, H.; Nielsen, N. M.; Fugger, L.; Melbye, M.; Hviid, A. Use of calcium channel blockers and Parkinson's disease. Am. J. Epidemiol., 2012, 175(7), 627-635.
96. Pinggera, A.; Lieb, A.; Benedetti, B.; Lampert, M.; Monteleone, S.; Liedl, K. R.; Tuluc, P.; Striessnig, J. CACNA1D de novo mutations in autism spectrum disorders activate Cav1. 3 L-type Ca2+ channels. Biol Psychiatry, 2015, 77, 816-822.
97. De Rubeis, S.; He, X.; Goldberg, A. P.; Poultney, C. S.; Samocha, K.; Ercument Cicek, A.; Kou, Y.; Liu, L.; Fromer, M.; Walker, S.; Singh, T.; Klei, L.; Kosmicki, J.; Fu, S. C.; Aleksic, B.; Biscaldi, M.; Bolton, P. F.; Brownfeld, J. M.; Cai, J.; Campbell, N. G.; Carracedo, A.; Chahrour, M. H.; Chiocchetti, A. G.; Coon, H.; Crawford, E. L.; Crooks, L.; Curran, S. R.; Dawson, G.; Duketis, E.; Fernandez, B. A.; Gallagher, L.; Geller, E.; Guter, S. J.; Sean Hill, R.; Ionita-Laza, I.; Jimenez Gonzalez, P.; Kilpinen, H.; Klauck, S. M.; Kolevzon, A.; Lee, I.; Lei, J.; Lehtimaki, T.; Lin, C. F.; Ma'ayan, A.; Marshall, C. R.; McInnes, A. L.; Neale, B.; Owen, M. J.; Ozaki, N.; Parellada, M.; Parr, J. R.; Purcell, S.; Puura, K.; Rajagopalan, D.; Rehnstrom, K.; Reichenberg, A.; Sabo, A.; Sachse, M.; Sanders, S. J.; Schafer, C.; Schulte-Ruther, M.; Skuse, D.; Stevens, C.; Szatmari, P.; Tammimies, K.; Valladares, O.; Voran, A.; Wang, L. S.; Weiss, L. A.; Jeremy Willsey, A.; Yu, T. W.; Yuen, R. K.; Cook, E. H.; Freitag, C. M.; Gill, M.; Hultman, C. M.; Lehner, T.; Palotie, A.; Schellenberg, G. D.; Sklar, P.; State, M. W.; Sutcliffe, J. S.; Walsh, C. A.; Scherer, S. W.; Zwick, M. E.; Barrett, J. C.; Cutler, D. J.; Roeder, K.; Devlin, B.; Daly, M. J.; Buxbaum, J. D. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature, 2014, 515, 209-215.
98. Ma, H.; Cohen, S.; Li, B.; Tsien, R. W. Exploring the dominant role of Cav1 channels in signalling to the nucleus. Biosci. Rep., 2013, 33(1), 97-101.
99. Yoshimizu, T.; Pan, J. Q.; Mungenast, A. E.; Madison, J. M.; Su, S.; Ketterman, J.; Ongur, D.; McPhie, D.; Cohen, B.; Perlis, R.; Tsai, L. H. Functional implications of a psychiatric risk variant within CACNA1C in induced human neurons. Mol. Psychiatry, 2014.
100. Post, R. M.; Frye, M. A.; Denicoff, K. D.; Leverich, G. S.; Dunn, R. T.; Osuch, E. A.; Speer, A. M.; Obrocea, G.; Jajodia, K. Emerging trends in the treatment of rapid cycling bipolar disorder: a selected review. Bipolar. Disord., 2000, 2(4), 305-315.
101. Hollister, L. E.; Trevino, E. S. Calcium channel blockers in psychiatric disorders: a review of the literature. Can. J. Psychiatry, 1999, 44(7), 658-664.
102. Radzicki, D.; Yau, H. J.; Pollema-Mays, S. L.; Mlsna, L.; Cho, K.; Koh, S.; Martina, M. Temperature-sensitive Cav1. 2 calcium channels support intrinsic firing of pyramidal neurons and provide a target for the treatment of febrile seizures. J. Neurosci., 2013, 33(24), 9920-9931.
103. Striessnig, J.; Zernig, G.; Glossmann, H. Human red-blood-cell calcium-antagonist binding sites. Eur. J. Biochem., 1985, 150, 67-77.
104. Bohm, M.; Swedberg, K.; Komajda, M.; Borer, J. S.; Ford, I.; Dubost-Brama, A.; Lerebours, G.; Tavazzi, L.; Investigators, S. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet, 2010, 376(9744), 886-894.
105. Zhang, Z.; Xu, Y.; Song, H.; Rodriguez, J.; Tuteja, D.; Namkung, Y.; Shin, H. S.; Chiamvimonvat, N. Functional Roles of Cav1. 3 (alpha1D) calcium channel in sinoatrial nodes: insight gained using gene-targeted null mutant mice. Circ. Res., 2002, 90(9), 981-987.
106. Martin, R. I.; Pogoryelova, O.; Koref, M. S.; Bourke, J. P.; Teare, M. D.; Keavney, B. D. Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials. Heart, 2014, 100(19), 1506-1510.
107. Cappato, R.; Castelvecchio, S.; Ricci, C.; Bianco, E.; Vitali-Serdoz, L.; Gnecchi-Ruscone, T.; Pittalis, M.; De Ambroggi, L.; Baruscotti, M.; Gaeta, M.; Furlanello, F.; Di Francesco, D.; Lupo, P. P. Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective, randomized, placebo-controlled, double-blind, crossover evaluation. J. Am. Coll. Cardiol., 2012, 60(15), 1323-1329.
108. Bangalore, S.; Messerli, F. H.; Cohen, J. D.; Bacher, P. H.; Sleight, P.; Mancia, G.; Kowey, P.; Zhou, Q.; Champion, A.; Pepine, C. J.; Investigators, I. Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy. Am. Heart J., 2008, 156(2), 241-247.
109. Moosmang, S.; Lenhardt, P.; Haider, N.; Hofmann, F.; Wegener, J. W. Mouse models to study L-type calcium channel function. Pharmacol. Ther., 2005, 106(3), 347-355.
110. Welling, A.; Ludwig, A.; Zimmer, S.; Klugbauer, N.; Flockerzi, V.; Hofmann, F. Alternatively spliced IS6 segments of the alpha 1C gene determine the tissue-specific dihydropyridine sensitivity of cardiac and vascular smooth muscle L-type Calcium channels. Circ. Res., 1997, 81(4), 526-532.
111. Kang, S.; Cooper, G.; Dunne, S. F.; Dusel, B.; Luan, C. H.; Surmeier, D. J.; Silverman, R. B. CaV1. 3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson's disease. Nat. Commun., 2012, 3, 1146.
112. Kang, S.; Cooper, G.; Dunne, S. F.; Luan, C. H.; Surmeier, D. J.; Silverman, R. B. Structure-activity relationship of N, N'-disubstituted pyrimidinetriones as Ca(V)1. 3 calcium channelselective antagonists for Parkinson's disease. J. Med. Chem., 2013, 56(11), 4786-4797.
113. Huang, H.; Ng, C. Y.; Yu, D.; Zhai, J.; Lam, Y.; Soong, T. W. Modest Cav1. 342-selective inhibition by compound 8 is betasubunit dependent. Nat. Commun., 2014, 5, 4481.
114. Ortner, N. J.; Bock, G.; Vandael, D. H.; Mauersberger, R.; Draheim, H. J.; Gust, R.; Carbone, E.; Tuluc, P.; Striessnig, J. Pyrimidine-2, 4, 6-triones are a new class of voltage-gated L-type Ca2+ channel activators. Nat. Commun., 2014, 5, 3897.
115. Patel, M. M.; Goyal, B. R.; Bhadada, S. V.; Bhatt, J. S.; Amin, A. F. Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs, 2009, 23(1), 35-58.
116. Lu, C. T.; Zhao, Y. Z.; Wong, H. L.; Cai, J.; Peng, L.; Tian, X. Q. Current approaches to enhance CNS delivery of drugs across the brain barriers. Int. J. Nanomedicine, 2014, 9, 2241-2257.
117. Yiu, S.; Knaus, E. E. Synthesis, biological evaluation, calcium channel antagonist activity, and anticonvulsant activity of felodipine coupled to a dihydropyridine-pyridinium salt redox chemical delivery system. J. Med. Chem., 1996, 39(23), 4576-4582.